Why Did Bristol-Myers Squibb (BMY) Climb Today?
The latest clinical news around Bristol-Myers Squibb (BMY) centers on late stage oncology and pulmonary fibrosis programs, featuring new Phase 3 readouts and a packed data slate heading into the 2026 ESMO Congress in Madrid.
For investors watching the tape, Bristol-Myers Squibb’s recent clinical updates are landing against a backdrop of firming momentum. A 1-day share price return of 3.08% at a last close of US$63.00 and a year-to-date share price return of 17.85% feed into a 1-year total shareholder return of 50.13% and a 5-year total shareholder return of 35.63%. This suggests that recent enthusiasm around late stage oncology and pulmonary fibrosis data is starting to build on a longer record of value creation through dividends and price gains.
Scan how Bristol-Myers Squibb’s late stage pipeline momentum compares with other research driven pharma stocks by reviewing the list of solid balance sheet and fundamentals (26 results) in the same space.
Bristol-Myers Squibb now trades only modestly below analyst targets and at a far steeper discount to some fair value models. After this sharp rebound, is the market’s caution still excessive or already ahead of itself?
Most Popular Narrative: 6% Undervalued
Against a last close of $63.00, the most followed narrative pegs Bristol-Myers Squibb’s fair value at about $66.71 using a 7.24% discount rate. That framing leans heavily on how the growth portfolio and late stage drugs might offset pressure from older therapies.
Ongoing shift in Bristol-Myers Squibb’s revenue mix toward its growth portfolio, which reached $7.6b in Q2 2026 and nearly 60% of total sales, supports the view that new products can increasingly offset legacy erosion and underpin future revenue and earnings.
See why 234 investors see Bristol-Myers Squibb as 6% undervalued.
Result: Fair Value of $66.71 (UNDERVALUED)
Still, this fair value story can crack if upcoming patent cliffs bite harder than expected or if safety setbacks slow key late stage Bristol-Myers Squibb launches.
Find out about the key risks to this Bristol-Myers Squibb narrative.
Next Steps
Sentiment around Bristol-Myers Squibb is split, with clear risks on one side and meaningful upside drivers on the other. Move quickly and test the narrative against your own expectations by reviewing the 4 key rewards and 3 important warning signs.
Looking for more investment ideas beyond Bristol-Myers Squibb?
If you’re serious about building a stronger portfolio, use the Simply Wall St Screener to surface fresh opportunities before they hit everyone else’s radar.
- Target stability first by scanning a 30 resilient stocks with low risk scores that have resilient business profiles when you want potential returns without taking on unnecessary shocks.
- Zero in on potential bargains by reviewing a 29 high quality undervalued stocks where quality metrics and pricing line up in a way that could reward patient investors.
- Build a watchlist of future contenders by checking a 20 high quality undiscovered gems before attention and capital start crowding into the same familiar tickers.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com